TY - JOUR. T1 - Down-regulation of osteoprotegerin expression as a novel biomarker for colorectal carcinoma. AU - Kim, Hyun Soo. AU - Yoon, Gun. AU - Do, Sung Im. AU - Kim, Sung Joo. AU - Kim, Youn Wha. PY - 2016/3/22. Y1 - 2016/3/22. N2 - A better understanding of tumor biology is important in the identification of molecules that are down-regulated in malignancy and in determining their role in tumor suppression. The aim of this study was to analyze osteoprotegerin (OPG) expression in colorectal carcinoma (CRC) and to investigate the underlying mechanism for changes in the expression of OPG. OPG expression was assessed in CRC tissue samples and cell lines. The methylation status of the OPG promoter region was determined, and the effects of demethylation on OPG expression were analyzed. The effects of recombinant OPG (rOPG) administration on cellular functions were also investigated. Clinical and prognostic implications of OPG protein expression in CRC patients were analyzed. The CRC tissues and ...
Thank you for your interest in spreading the word on Circulation.. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. ...
The present study demonstrated in a large population of type 2 diabetes patients with no history of cardiovascular disease and relative short diabetes duration that plasma OPG levels were significantly increased in those with carotid arterial disease and PAD compared to patients without these manifestations. This was, however, not the case for patients with subtle signs of myocardial ischemia versus those without. When adjusted for age, HbA1c and U-albumin creatinine ratio in a multivariate logistic regression analysis, plasma OPG levels was associated with carotid arterial disease, but not with PAD or myocardial ischemia.. OPG is an important regulating molecule in bone turnover, and plasma OPG has been shown to correlate to bone and arterial diseases [21]. Of note, plasma OPG has been demonstrated to be an independent risk factor for the 10-year incidence of CVD and vascular mortality [22]. In diabetes mellitus, accumulation of OPG may be part of the generalized matrix changes seen in the ...
353 Serum osteoprotegerin/osteoclastogenesis-inhibitory factor during pregnancy and lactation and the relationship with calciumregulating hormones and bone turnover markers H Uemura, T Yasui, M Kiyokawa, A Kuwahara, H Ikawa, T Matsuzaki, M Maegawa, H Furumoto and M Irahara Department of Obstetrics and Gynecology, University of Tokushima, School of Medicine, 3-18-15, Kuramoto-cho, Tokushima 770-8503, Japan (Requests for offprints should be addressed to H Uemura; Email: [email protected]) Abstract Pregnancy and lactation induce dynamic changes in maternal bone and calcium metabolism. A novel cytokine termed osteoprotegerin (OPG)/osteoclastogenesisinhibitory factor (OCIF) was recently isolated; this cytokine inhibits osteoclast maturation. To define the effects of pregnancy and lactation on circulating OPG/OCIF in mothers, we studied the changes in the levels of OPG/ OCIF as well as those of calcium-regulating hormones and biochemical markers of bone turnover in the maternal circulation during ...
OBJECTIVE: Osteoprotegerin ligand (OPGL) is a newly discovered molecule, which is expressed by osteoblasts/bone stromal cells. This ligand and M-CSF are now known to be essential for osteoclast differentiation from marrow and circulating precursors. This study examined whether OPGL and its soluble receptor osteoprotegerin (OPG), influenced osteoclast formation from human arthroplasty derived macrophages, to determine if the effects of OPGL and OPG on these cells could contribute to the osteolysis of aseptic loosening. METHODS: OPGL (+/- dexamethasone/M-CSF) was added to cultures of macrophages isolated from the pseudomembrane of loosened hip arthroplasties incubated on glass coverslips and dentine slices. OPG was added to cocultures of arthroplasty derived macrophages and UMR106 osteoblast-like cells. Osteoclast differentiation in long term cultures was assessed by expression of macrophage (CD14) and osteoclast markers (tartrate resistant acid phosphatase (TRAP), vitronectin receptor (VNR) and lacunar
Results. In patients with RA, age, body mass index (BMI), rheumatoid factor (RF) positivity, anticyclic citrullinated peptide (anti-CCP) antibody positivity, and joint erosion status were associated with OPG concentrations [partial R (p) = 0.175 (0.03), −0.277 (0.0009), 0.323 (, 0.0001), 0.217 (0.008), and 0.159 (0.05), respectively]. Median (interquartile range) OPG concentrations increased from 6.38 (3.46-9.31) to 7.07 (5.04-10.65) and 8.64 (6.00-11.52) ng/ml in controls and patients with RA who had CVD and those who did not, respectively (p = 0.0002). Upon adjustment for age, sex, traditional risk factors, and BMI in mixed regression models, OPG concentrations remained lower in controls compared to patients with RA without CVD (p = 0.05) and in the latter compared to those with CVD (p = 0.03); the association of OPG concentrations with CVD among patients with RA also persisted after additional adjustment for RF and anti-CCP antibody positivity, and erosion status (p = 0.04). ...
Heart failure (HF) is a disabling condition involving complex vascular, neurohormonal and immune systems interactions. Osteoprotegerin (OPG), a bone-regulatory cytokine, has been suggested to play a...
BACKGROUND: Elevated levels of osteoprotegerin, a secreted tumor necrosis factor-related molecule, might be associated with adverse outcomes in patients with coronary artery disease. We measured plasma osteoprotegerin concentrations on hospital admission, at discharge, and at 1 and 6 months after discharge in a predefined subset (n=5135) of patients with acute coronary syndromes in the PLATO (Platelet Inhibition and Patient Outcomes) trial. METHODS AND RESULTS: The associations between osteoprotegerin and the composite end point of cardiovascular death, nonprocedural spontaneous myocardial infarction or stroke, and non-coronary artery bypass grafting major bleeding during 1 year of follow-up were assessed by Cox proportional hazards models ...
All Osteoprotegerin tagged posts will be found here. Check the latest Osteoprotegerin from medipiture.com. Osteoprotegerin Updated on February 2018.
Recent works demonstrated the difference of calcification genesis between carotid and femoral plaques, femoral plaques being more calcified. It has been clearly demonstrated that the molecular triad osteoprotegerin (OPG)/Receptor Activator of NFkB (RANK)/RANK Ligand (RANKL) exerts its activities in the osteoimmunology and vascular system. The aim of this study was to determine their expression and their potential role in calcifications of the atheromatous plaques located in two different peripheral arterial beds, carotid and femoral. The expression of OPG, RANK and RANKL was analyzed by immunochemistry in 40 carotid and femoral samples. Blood OPG and RANKL were quantified using specific ELISA assays. OPG staining was more frequently observed in carotid than in femoral plaques, especially in lipid core. Its expression correlated with macrophage infiltration more abundantly observed in carotid specimens. Surprisingly, serum OPG concentration was significantly lower in carotid population compared to
Osteoprotegerin (OPG), receptor activator for nuclear factor kappa beta ligand (RANKL) and tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) are newly discovered members of the tumour necrosis factor-alpha receptor superfamily. While their role in bone metabolism is well described, their function within the vasculature is poorly understood. OPG inhibits vascular calcification in vitro and high serum levels have been demonstrated in type 2 diabetes, but serum RANKL and TRAIL and their potential correlation with well-established biomarkers of subclinical vascular inflammation such as high-sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6) have not been described.; Sixty-two patients with well-controlled type 2 diabetes and an age, gender and body mass index-matched group of 58 healthy individuals were recruited. Serum OPG, RANKL and TRAIL were measured using commercial enzyme-linked immunosorbent assays, as were hsCRP and IL-6.; Serum OPG, IL-6 and hsCRP levels, but not ...
Bone erosion is a hallmark of rheumatoid arthritis. Recent evidence from experimental arthritis suggests that osteoclasts are essential for the formation of local bone erosions. Two essential regulators of osteoclastogenesis have recently been described: the receptor-activator of nuclear factor kappa B ligand, which promotes osteoclast maturation, and osteoprotegerin (OPG), which blocks osteoclastogenesis. The present review summarizes the current knowledge on the role of osteoclasts in local bone erosion. In addition, the role of OPG as a therapeutic tool to inhibit local bone erosion is addressed. Finally, evidence for OPG as an inhibitor of systemic inflammatory bone loss is discussed.
Abcams Osteoprotegerin ELISA Kit suitable for Cell culture supernatant, Serum, Plasma, Cell Lysate in human. Reliably quantify 1 pg/ml of Osteoprotegerin.
Objectives: To examine whether treatment with anti-tumour necrosis factor (TNF) α prevents loss of bone mineral density (BMD) at the spine and hip (generalised) and in the hands (local) of patients with rheumatoid arthritis, and to study the changes in markers of bone metabolism, including receptor activator of the NFκB ligand (RANKL) and osteoprotegerin (OPG), during anti-TNF treatment.. Patients and methods: 102 patients with active rheumatoid arthritis, who were treated with infliximab during 1 year, were included in this open cohort study. The BMD of the spine and hip (dual x ray absorptiometry) and hands dual x ray radiogrammetry was measured before the start of treatment and after 1 year. Changes in osteocalcin formation, β-isomerised carboxy terminal telopeptide of type 1 collagen (β-CTx, resorption), RANKL and OPG were determined at 0, 14, 30 and 46 weeks.. Results: The BMD of the spine and hip was unchanged during treatment with infliximab, whereas BMD of the hand decreased ...
in Clinical & Experimental Immunology (2004), 138(3), 491-498. Crohns disease (CD) is associated with low bone mass due to chronic inflammation and other factors. Receptor activator of NF-kappaB ligand (RANKL), its receptor RANK and its decoy receptor ... [more ▼]. Crohns disease (CD) is associated with low bone mass due to chronic inflammation and other factors. Receptor activator of NF-kappaB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin (OPG) are potentially involved in this process as they regulate osteoclastogenesis and are influenced by pro-inflammatory cytokines. The aim of this study was to determine the levels of soluble RANKL (sRANKL), RANK and OPG expression both in the serum and in the colon of CD patients. Levels of sRANKL and OPG were assessed in the serum and the supernatants of cultured colonic biopsies in patients with CD and controls by ELISA. RANK expression was explored by immunostaining and immunofluorescence of fixed colonic samples. OPG and ...
The present study demonstrates that elevated plasma levels of the soluble decoy receptor OPG are associated with adverse prognosis in patients who develop HF in the acute phase after AMI. Furthermore, the predictive value of OPG at baseline provided risk prediction independent of creatinine clearance, N-BNP, hsCRP, and other known predictors of mortality and cardiovascular events after AMI. Of importance, OPG remained a significant predictor of cardiovascular death also when correcting for N-BNP, an important prognostic marker in HF patients. Finally, in non-survivors plasma OPG levels were not only increased in the acute phase of AMI, but also during follow-up, suggesting that OPG may be valuable for monitoring HF patients both immediately after AMI as well as during follow-up.. An increasing number of osteogenic factors have been detected in atherosclerotic plaques and received attention in relation to vascular biology (3-5). The OPG/receptor activator of NF-kappaBsystem plays an important ...
Thank you for your interest in spreading the word on Arteriosclerosis, Thrombosis, and Vascular Biology.. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. ...
With the increasing age of people living with HIV/AIDS, age-induced osteoporosis is likely to be compounded by HIV/AIDS and HAART-associated bone loss. Mechanistically, osteoclasts the cells responsible for bone resorption form under the influence of the key osteoclastogenic cytokine Receptor- Activator of NF-KB (RANKL). The osteoclastogenic and proresorptive activities of RANKL are moderated by its physiological decoy receptor osteoprotegerin (OPG). Imbalance in the ratio of RANKL to OPG alters osteoclastic bone resorption and lead to osteoporosis. Activated T- and B-cells are a major source of RANKL, while normal physiological B-cells are a major source of OPG. T-cells regulate the production of OPG by B-cells. Thus changes in the immune system induced by HIV/AIDS and/or by HAART could affect B-cell and T-cells RANKL and OPG production. Indeed, data from our group shows that in an animal model of HIV/AIDS, the HIV-1 Transgenic rat, the development of osteoporosis is recapitulated as observed ...
In this report we investigated the role of the newly described TNF-related protein, OPGL, in OC activation. Previously, Lacey et al. (1998) and Yasuda et al. (1998b) identified OPGL/ODF as the long sought OC differentiation factor. Direct expression cloning was used independently by the two groups to identify OPGL/ODF as the ligand for OPG/OCIF. OPG is expressed only as a soluble form and is now believed to act as a soluble decoy receptor to regulate the action of OPGL on differentiation of OCs. The data presented in the two reports provide strong evidence that OPGL acts directly on a population of OC progenitors, and together with CSF-1 induces terminal differentiation into mature, active OCs. Our data also showed that OPGL activated mature OCs to resorb bone in vitro (Lacey et al., 1998), and recent work supports our previous results (Fuller et al., 1998).. In this report we have shown that OPGL or agonist antibodies to its receptor, RANK, act directly on fully differentiated, mature OCs ...
Sigma-Aldrich offers abstracts and full-text articles by [A Esteghamati, R Azizi, M Ebadi, S Noshad, M Mousavizadeh, M Afarideh, M Nakhjavani].
Though significant progress has been made towards new diagnostic approaches for early detection of acute kidney injury (AKI) induced by different factors, there is still an urgent demand for a more specific and predictive biomarker for each type. The aim of this study is to unravel the potential diagnostic utility of circulating osteoprotegerin (OPG) in septic patients who developed AKI in the ICU, compared to cystatin C (a renal function maker) and KIM-1 (a kidney damage marker).. ...
AbstractThe aim of this study was to investigate the effects of two consecutive Crossfit® training sessions (24 hours apart) designed to enhance work-capacity that involved both cardiovascular and muscular exercises on cytokines, muscle power, blood lactate and glucose. Nine male members of the CrossFit® community (age 26.7 ± 6.6 years; body mass 78.8 ± 13.2 kg; body fat 13.5 ± 6.2 %; training experience 2.5 ± 1.2 years) completed two experimental protocols (24 hours apart): 1) strength and power exercises 2) gymnastic movements and 3) metabolic conditioning as follows: 10 min of as many rounds as possible (AMRAP) of 30 double-unders and 15 power snatches (34kg). The same sequence as repeated on session 2 with the following metabolic conditioning: 12 min AMRAP of: row 250m and 25 target burpees. Serum interleukin-6 (IL-6), IL-10 and osteoprotegerin were measured before, immediately post and 24 h after training 1, immediately post, 24 h and 48 h after training session 2. Peak and mean power were
There are no specific protocols for Recombinant human Osteoprotegerin protein (ab73829). Please download our general protocols booklet
购买我们的重组人Osteoprotegerin蛋白。Ab73829为有活性的蛋白片段,在中生产并经过SDS-PAGE实验验证。Abcam提供免费的实验方案,操作技巧及专业的支持。
The following example illustrates the basic format: 1. Body JJ, Greipp P, Coleman RE, et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related metastases. Cancer. 2003;97(3)(suppl):887-892. If the supplement is numbered, and there is no issue number, use the following form: 2. McDougle CJ, Stigler KA, Posey DJ. Treatment of aggression in children and adolescents with autism and conduct disorder. J Clin Psychiatry. 2003; 64(suppl 4):16-25. If the supplement is numbered, and there is an issue number, use the form below: 3. Crino L, Cappuzzo F. Present and Less ...
The following example illustrates the basic format: 1. Body JJ, Greipp P, Coleman RE, et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related metastases. Cancer. 2003;97(3)(suppl):887-892. If the supplement is numbered, and there is no issue number, use the following form: 2. McDougle CJ, Stigler KA, Posey DJ. Treatment of aggression in children and adolescents with autism and conduct disorder. J Clin Psychiatry. 2003; 64(suppl 4):16-25. If the supplement is numbered, and there is an issue number, use the form below: 3. Crino L, Cappuzzo F. Present and
Osteoclasts uses MMP, H+, proteolytic enzimes (MMP, cathepsins): Bone resorption products: Ca, cytokines (TGFB, IFG), degradation of type I collagen. The cytokines are major players in bone metastasis. Osteoclast activity is the result of interplay of RANK (in onsteoclast), RANKL, and osteoprotegerin (blocks RANKL). The RANK system is the common pathway. The balance between RANKL and Osteoprotegerin establishes whether there is net bone loss. Estrogen loss during menopause boosts RANKL+ T-cells in the bone. Sex hormone deprivation casuses significant bone loss through RANKL over-expression. (Kanis JA, JCO, 2011 ...
Sigma-Aldrich offers abstracts and full-text articles by [Hongyan Zhao, Xuezhong Liu, Hui Zou, Nannan Dai, Lulian Yao, Xiao Zhang, Qian Gao, Wei Liu, Jianhong Gu, Yan Yuan, Jianchun Bian, Zongping Liu].
Biomedica offers ELISA kits for the determination of biomarkers of bone metabolism. Our assay portfolio ranges from Osteoprotegerin and a highly sensitive free soluble RANKL assay to biomarkers of the Wnt signaling pathway such as Periostin, Sclerostin and DKK-1 and the osteocyte derived FGF23.
Osteoclasts;Estrogen;Postmenopause;Bone and Bones;Bone Remodeling;RANK Ligand;Carrier Proteins;Mutation;Osteoporosis, Postmenopausal;Osteoprotegerin;Glycoproteins;Receptor Activator of Nuclear Factor-kappa B;Receptors, Cytoplasmic and ...
Affiliation (Current):徳島大学,大学院医歯薬学研究部(医学域),准教授, Research Field:Hygiene,Obstetrics and gynecology,Public health/Health science,衛生学・公衆衛生学,Basic Section 58030:Hygiene and public health-related: excluding laboratory approach, Keywords:脈派伝播速度,メタボリック症候群,動脈硬化,動脈スティフネス,生活習慣病,糖尿病,死亡率,osteoprotegerin,エストロゲン,GnRH-agonist, # of Research Projects:7, # of Research Products:77, Ongoing Project:Analysis of associations between dietary pattern, nutient pattern, and metabolic syndrome, mortality and cancer incidence
BioMed Research International is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies covering a wide range of subjects in life sciences and medicine. The journal is divided into 55 subject-specific sections.
BioMed Research International is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies covering a wide range of subjects in life sciences and medicine. The journal is divided into 55 subject areas.
Wear particles derived from implant biomaterials induce a pronounced foreign body macrophage response in both the pseudocapsule and pseudomembrane surrounding arthroplasty components.28 29 The clinical severity and rapidly of onset of aseptic loosening can be correlated with both the amount of wear particle deposition and the extent of the macrophage response in these periprosthetic tissue.30-32 In this study we have shown that the capacity of arthroplasty macrophages to differentiate into osteoclasts is OPGL dependent and that this process is inhibited by OPG in a dose dependent fashion.. Our results show that the inflammatory foreign body macrophage infiltrate in periprosthetic tissues, surrounding loose arthroplasty components, contains mononuclear osteoclast precursors and that these cells express the phenotypic characteristics of macrophages and not osteoclasts. Post-mitotic osteoclast precursors of marrow origin have been shown to lose and to acquire macrophage and osteoclast markers ...
Bone Biology and the Role of RANK/RANKL/OPG Pathway. Speaker: Robert G. Josse, MD, Division of Endocrinology & Metabolism, St. Michaels Hospital; Professor of Medicine, University of Toronto, Toronto, ON.. Advances in the understanding of bone biology and the role of the RANK/RANKL/OPG pathway have opened new treatment avenues for osteoporosis. To facilitate understanding of the "new biology," Dr. Robert Josse first reviewed determinants of bone strength.. Trabecular bone, a spongy network of delicate plates of bone known as trabeculae, constitutes 20% of skeletal mass but accounts for ~80% of bone turnover. In contrast, cortical bone constitutes 80% of mass but ~20% of turnover. The interior surface of cortical bone, the endosteum, is the primary site of remodeling and metabolic activities while the exterior surface, the periosteum, is the site of new bone formation.. Remodeling, Dr. Josse noted, takes place continuously: tiny packets of bone throughout the skeleton constantly undergo this ...
Because of the excess of androgen caused by 21-OHD CAH, women with CAH may exhibit some male-like characteristics. Glucocorticoids are a member of a class of drugs called corticosteroids, which are used in hormone replacement therapy. In order to counteract the effects of 21-OHD CAH, women with the disease are given hormone replacement therapy with glucocorticoids beginning at infancy. Glucocorticoids are known to cause bone loss. Despite many years of treatment with glucocorticoids, however, young women with 21-OHD CAH seem to be protected against bone loss. Researchers believe that the increased androgen levels in these women leads to increased estrogen levels, which in turn increases OPG production. The increase in OPG levels may protect women against bone loss. This study will evaluate bone density and OPG levels in women with and without 21-OHD CAH to determine the relationship between OPG and bone loss.. Participants in this observational study will attend only one study visit. At this ...
Receptor activator of NF-kappaB ligand (RANKL), its signaling receptor RANK, and its decoy receptor osteoprotegerin (OPG) constitute a molecular triad that is critical in regulating bone remodeling, and also plays multiple roles in the immune system. OPG binds RANKL directly to block its interaction with RANK. In this article, we report the 2.7-A crystal structure of human RANKL trimer in complex with the N-terminal fragment of human OPG containing four cysteine-rich TNFR homologous domains (OPG-CRD). The structure shows that RANKL trimer uses three equivalent grooves between two neighboring monomers to interact with three OPG-CRD monomers symmetrically. A loop from the CRD3 domain of OPG-CRD inserts into the shallow groove of RANKL, providing the major binding determinant that is further confirmed by affinity measurement and osteoclast differentiation assay. These results, together with a previously reported mouse RANKL/RANK complex structure, reveal that OPG exerts its decoy receptor function ...
Background: Matrix Metalloproteinases (MMPs)-2/9 and Osteoprotegerin (OPG) are considered key enzymes in the pathogenesis of the abdominal aortic aneurysm (AAA), with elevated levels in diseased aorta and patient sera. The goal of the study was to find out if there is evidence that these biomarkers are suitable for risk assessment and follow up after aneurysm repair. Furthermore no data exists on the effect of statins on serum activity of MMP-2/9 and OPG. Methods: In 63 patients undergoing elective aneurysm repair serum levels of MMP-2/9 and OPG were measured on the day before and seven days after surgery using an enzyme immunoassay. Levels were correlated to aneurysm diameter, time of sampling and statin therapy. Also, tissue samples of diseased aorta were tested for immunohistochemical features. Results: There was no significant correlation between serum activity and AAA diameter in patients with infrarenal abdominal aortic aneurysm. On day seven after surgery there was a significant increase ...
Background: Matrix Metalloproteinases (MMPs)-2/9 and Osteoprotegerin (OPG) are considered key enzymes in the pathogenesis of the abdominal aortic aneurysm (AAA), with elevated levels in diseased aorta and patient sera. The goal of the study was to find out if there is evidence that these biomarkers are suitable for risk assessment and follow up after aneurysm repair. Furthermore no data exists on the effect of statins on serum activity of MMP-2/9 and OPG. Methods: In 63 patients undergoing elective aneurysm repair serum levels of MMP-2/9 and OPG were measured on the day before and seven days after surgery using an enzyme immunoassay. Levels were correlated to aneurysm diameter, time of sampling and statin therapy. Also, tissue samples of diseased aorta were tested for immunohistochemical features. Results: There was no significant correlation between serum activity and AAA diameter in patients with infrarenal abdominal aortic aneurysm. On day seven after surgery there was a significant increase ...
RANK-ligand and osteoprotegerin as biomarkers in the differentiation between periprosthetic joint infection and aseptic prosthesis loosening
An article in this issue of the American Journal of Nephrology by Avila-Diaz et al. [6] provides more data. OPG is a glycoprotein in the tumor necrosis factor-receptor superfamily, and is known to inhibit osteoclastogenesis by acting as a decoy receptor for the receptor activator of nuclear factor-κβ ligand. In vascular smooth muscle cells, receptor activator of nuclear factor-κβ ligand appears to promote calcification, whereas the action of OPG may be protective [7]. Many retrospective studies have shown that elevated serum OPG levels are associated with the presence and severity of coronary artery disease and CAC. Retrospective studies, however, cannot show anything more than an association.. Therefore, the study by Avila-Diaz et al. [6] provides important additional information, as this appears to be the first prospective study to examine OPG and VC in patients with CKD. This study followed patients, on incident peritoneal dialysis for less than 3 months, for 1 year and measured ...
Previous studies of opg-transgenic and opg−/− mice have revealed that OPG plays a vital role in regulating osteoclast production in the bone marrow (2, 12, 33). In this study, we have shown that OPG also regulates B lymphopoiesis, most notably at the pro-B cell and transitional B cell stages.. Clues as to how OPG may regulate B lymphopoiesis may come from examining OPGs role in regulating bone metabolism. In the absence of OPGs normal "braking" of osteoclast maturation, the opg−/− mice exhibited drastic increases in cortical bone porosity that was accompanied by a striking acceleration of new apposition on periosteal and intracortical surfaces. Preliminary data indicate most pronounced increases in mineralization in those parts of the skeleton under greatest mechanical load, the long bones and the mandibular body, leading to bone hypertrophy on a gross morphological level. We hypothesize that because the quality and, therefore, strength of bone is compromised by increased bone ...
Receptor activator of nuclear factor-kappa B (RANK)-RANK ligand (RANKL) signaling promotes mammary tumor development in experimental models. Circulating concentrations of soluble RANKL (sRANKL) may influence breast cancer risk via activation of RANK signaling; this may be modulated by osteoprotegerin (OPG), the decoy receptor for RANKL. sRANKL and breast cancer risk by hormone receptor subtype has not previously been investigated. A case-control study was nested in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. This study included 1,976 incident invasive breast cancer cases [estrogen receptor positive (ER+),n= 1,598], matched 1:1 to controls. Women were pre- or postmenopausal at blood collection. Serum sRANKL was quantified using an ELISA, serum OPG using an electrochemiluminescent assay. Risk ratios (RR) and 95% confidence intervals (95% CI) were calculated using conditional logistic regression. Associations between sRANKL and breast cancer risk differed by ...
Receptor activator of nuclear factor-kappa B (RANK)-RANK ligand (RANKL) signaling promotes mammary tumor development in experimental models. Circulating concentrations of soluble RANKL (sRANKL) may influence breast cancer risk via activation of RANK signaling; this may be modulated by osteoprotegerin (OPG), the decoy receptor for RANKL. sRANKL and breast cancer risk by hormone receptor subtype has not previously been investigated. A case-control study was nested in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. This study included 1,976 incident invasive breast cancer cases [estrogen receptor positive (ER+),n= 1,598], matched 1:1 to controls. Women were pre- or postmenopausal at blood collection. Serum sRANKL was quantified using an ELISA, serum OPG using an electrochemiluminescent assay. Risk ratios (RR) and 95% confidence intervals (95% CI) were calculated using conditional logistic regression. Associations between sRANKL and breast cancer risk differed by ...
Several studies have demonstrated that P-OPG is a strong prognostic cardiovascular risk marker in diabetic and non-diabetic populations [2-5]. For example, we have found that in 283 type 2 diabetic subjects followed for 17 years, high P-OPG predicted all-cause and cardiovascular mortality, independently of known CVD risk markers including levels of albuminuria and P-NT-proBNP[2]. The latter study was not designed to examine mechanisms behind the increased P-OPG and cardiovascular death. In the current cross-sectional study, we demonstrated that P-OPG was a risk marker for the presence of subclinical CAD, which again may contribute to the association with CVD mortality. OPG expression is increased in the atherosclerotic arterial wall and P-OPG has been suggested to reflect the arterial OPG content and therefore be a surrogate marker of arterial damage[8]. Along this line, OPG is up-regulated in calcified coronary plaques[20] and P-OPG has been associated with angiographic disease severity, ...
Many of the elevated markers evaluated by Brand and colleagues in pancreatic cancer patients were acute phase reactants (SAA, ICAM-1, CRP, osteoprotegerin) whose expression is regulated by inflammatory cytokines and whose primary source is probably not pancreatic cancer cells. These markers are elevated in many inflammatory conditions and have limited diagnostic utility. For example, elevations of ICAM-1 and/or osteoprotegerin are observed not only in chronic inflammatory conditions but are also in patients with conditions common to a pancreatic cancer population, including diabetes, hypercholesterolemia, atherosclerotic disease, obesity, and hypertension. This observation likely explains why markers that did best in the Brand study were proteins thought to arise predominantly from pancreatic cancer cells (CA19-9, CEA, and TIMP-1). Although some of the acute-phase reactant markers tested did show some ability to discriminate between pancreatic cancers and the benign pancreatic conditions, their ...
Results: MetS patients from the entire group of 47 patients were divided into four cohorts depending on 25(OH)D3 levels. The groups comprised patients with 25(OH)D3 levels above 100 nmol/L (n = 10), patients with levels from 50 to 100 nmol/L (n = 12), patients with levels from 30 to 50 nmol/L (n = 14), and patients with levels below 30 nmol/L (n = 11). There were significant differences between the MetS cohorts in terms of haemoglobin A1c (HbA1c) (P = 0.038), the homeostasis model assessment for insulin resistance (HOMA-IR) (P = 0.042), triglycerides (P = 0.044), osteoprotegerin (P=0.028), adiponectin (P = 0.018), high density lipoprotein cholesterol (HDL-C) (P=0.036), and CD14+СD309+Tie-2+ cells. Vitamin D deficiency in a multivariate log-linear regression model appeared to be an independent predictor of the numbers of CD14+СD309+ Tie-2+ cells (OR 1.12; 95% CI 1.06 to 1.19; P = 0.002). Osteoprotegerin, high sensitivity C-reactive protein (hs-CRP), and adiponectin have been shown to make an ...
As noted above, OPG is an endogenous inhibitor of RANKL signaling that limits arterial calcium accumulation during development. Recently, the impact of pharmacological inhibition of RANKL by OPG has been evaluated in the above preclinical models of atherosclerosis and arterial calcification. Interestingly, very distinct responses are observed with OPG administration in LDLR−/− and apoE−/− mice.28,43 Morony et al28 first evaluated the male LDLR−/− mouse, the dynamics of endogenous RANKL/OPG signaling during disease initiation and progression, and the impact of exogenous OPG administration. Serum RANKL measurements demonstrated that progression of vascular disease over 5 months of dietary cholesterol challenge closely tracks the progressive recovery of circulating RANKL after an early phase of diet-induced suppression.28 Early diet-induced increases in OPG, a presumed adaptive mechanism to protect against untoward RANKL signaling,36 exhibited no dynamic change with progression.28 As ...
Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176 ...
OPG antibody [13H21] (tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)) for WB. Anti-OPG mAb (GTX53424) is tested in Mouse samples. 100% Ab-Assurance.